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Abstract
Increased production volumes and a broadening application spectrum of graphene have raised
concerns about its potential adverse effects on human health. Numerous reports demonstrate that
graphene irrespective of its particular form exerts its effects on a widest range of living organisms,
including prokaryotic bacteria and viruses, plants, micro- and macro-invertebrates, mammalian
and human cells and whole animals in vivo. However, the available experimental data is frequently
a matter of significant divergence and even controversy. Therefore, we provide here a critical
analysis of the most recent (2015–2016) reports accumulated in the graphene-related materials
biocompatibility and toxicology field in order to elucidate the cutting edge achievements, emerging
trends and future opportunities in the area. Experimental findings from the diverse in vitro and
in vivo model systems are analysed in the context of the most likely graphene exposure scenarios,
such as respiratory inhalation, ingestion route, parenteral administration and topical exposure
through the skin. Key factors influencing the toxicity of graphene and its complex derivatives as
well as potential risk mitigation approaches exploiting graphene physicochemical properties,
surface modifications and possible degradation pathways are also discussed along with its emerging
applications for healthcare, diagnostics and innovative therapeutic approaches.

1. Introduction
From the utmost importance point of human health
and safety perspective, the continuously expanding
range of applications of carbonaceous nanomaterials
dictates a necessity for the strict assessment of the
associated hazards, potential risks in the context of the
most likely exposure scenarios and the investigation
of possible risk mitigation measures. Graphene in
particular, being at the forefront of 2D representatives
since the announcement of a Nobel Prize in the area in
2010, deserves a special level of merit and scrutiny alike.
The field of graphene toxicity has been previously
overviewed in a number of publications addressing
the complex issues of the synthetic routes [1], nanointerplay of biological objects and graphene as a
function of its physiochemical properties [2], environ
mental exposure [3], tissue engineering [4], reproductive and developmental toxicity [5], biosensors and
bioimaging applications [6–8], new nanodrug deliv© 2017 IOP Publishing Ltd

ery systems, advanced treatment and theranostic tools
development [7, 9–14].
However, very recently accumulated experimental
evidence demonstrates that there is still a considerable
amount of uncertainty and sometimes controversy over
the current findings related to the biocompatibility,
toxicity and potential applications of graphene-based
nanomaterials. This partially owes to the discrepancies
in the experimental setups and approaches at different
research centres, and to a significant extent also to the
diversity of graphene forms available at the moment.
Graphene is a single-layer 2D carbon nanomaterial
that is made up of sp2 hexagonal networks where strong
covalent bonds are formed between adjacent carbon
atoms [15]. 3D graphite is made up of layers of these
hexagonal networks whereas rolled up sheets form 2D
carbon nanotubes [16]. Graphene has many different
forms better known as the graphene family nanomat
erials, such as graphene oxide, reduced graphene oxide,
single or few layer graphene [17], nanoribbons [18, 19],
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Figure 1. Main sources, exposure routes of graphene to living organisms and their experimental equivalents, and the ecosystems
inhabitants subject to most significant exposure risk. The figure is an original illustration by the authors.

nanosheets, nanoonions [20] and graphene quantum
dots [19, 21]. All of them have very different edge
effects and surface chemistries, for example graphene
has a hydrophilic surface allowing for biointeractions
predominantly at the edges or defect sites whereas graphene oxide is hydrophilic due to the many oxygen
containing functional groups on the basal plane and
edges, thus allowing for stable dispersions in water [22].
The awareness of the potentially negative consequences of graphene exposure to living organisms in
general has been previously raised in this journal [23].
Therefore, we have aimed here to provide a more comprehensive overview of the most recent developments
in the graphene-related biocompatibility and toxicology
field predominantly accumulated over the past couple
of years in order to elucidate the cutting edge trends
and future opportunities in the area. Graphene and its
derivatives are being increasingly exploited in advanced
structures and devices designed to be used in electronics, catalysis, ICT and healthcare. In this case, one must
consider the potential adverse environmental and health
impact of graphene materials when released from the
devices at the end of their lifecycle, largely focussing
on the evaluation of potential hazards associated with
the individual device components and implemented
materials. On the other hand, a number of innovative
systems for drug delivery which assume an immediate contact with human cells upon topical or systemic
administration has been also suggested. Therefore, in
order to get a comprehensive picture of the emerging
‘nano-risks’ fully applicable to graphene and graphenederived nanomaterials, devices and complex systems
such as those intended for drug delivery, a multi-step
approach must be implemented including hazard identification, characterisation and assessment of the most
likely exposure scenarios. The identification and characterisation of the potential hazards is expected to involve
2

a maximally detailed physicochemical characterisation
of the nanomaterial under question and to include such
parameters as size, shape, geometry and surface properties, aspect ratio, charge, water solubility, aggregation
state, chemical composition including the potential
contaminants during the synthetic process etc. In the
industrial settings, one must also take into account
such factors as the nanomaterial production volumes,
material flow and potential particle release routes into
the environment. Exposure assessment shall address a
whole spectrum of living biological systems, including
bacteria and other microorganisms, in vitro cultured
primary cells and established cell lines, invertebrates and
primitive multicellular organisms, lower vertebrates and
in vivo in experimental animals implementing scenarios
and models most closely imitating human contact with
nanomaterials in real life. Here we provide the examples
of such assessment in a wide range of living organisms.
The most common exposure routes of humans to
nanomaterials are via inhalation, gastrointestinal tract
after ingestion, topical exposure through the skin and
parenteral or intravenous route, especially by intentional systemic administration. Both acute and chronic
long-term exposure effects along with the nanomat
erial bio-persistence and accumulation patterns must
be thoroughly investigated in order to gain a most complete toxicological information. We analyse the most
recently accumulated reports on graphene toxicity in
the context of the above mentioned factors (figure 1).
The possibilities of relevant risk reduction and management are evaluated including the opportunities to
exploit graphene physicochemical properties, surface
modifications and possible catabolic degradation pathways. Finally we provide a critical assessment of the new
emerging applications of graphene-enabled products
for healthcare, diagnostics and innovative therapeutic
approaches.
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2. Graphene effects on microorganisms,
protozoa, plants, invertebrates and lower
vertebrates
2.1. Bacteria and viruses
Among the earlier reports addressing the influence
of fundamental physical characteristics of graphene
materials on microorganisms is the study by Liu
et al [24] who have revealed the dependence of
antibacterial activity of graphene oxide sheets on
their lateral dimension. In this study carried out
in the Escherichia coli model the authors explored
the properties of graphene oxide sheets with over
100 times lateral size difference. As a result, it was
established that larger graphene oxide sheets possessed
a higher antibacterial activity than the smaller ones in
a time- and concentration-dependent manner. As this
phenomenon was not related either to the graphene
sheets aggregation state or their oxidation capacity, it
has been suggested that the bactericidal effect is mostly
due to the specifics of direct interactions of graphene
oxide particles of different size with bacterial cell walls,
whereby larger graphene sheets cover the bacteria
preventing the proliferation, whilst the similar in nature
but smaller nanomaterials just adhere to the surface of
bacteria and do not provide an efficient isolation of
cells from the environment. A more recent work by
Perreault et al [25]conducted in the same E. coli model
microorganism system, graphene oxide sheets ranging
between 0.01 and 0.65 µm2 have been investigated
for their antibacterial activity. They have established
that surface coating using the smaller 0.01 µm2 size
nanosheets possessed a four times higher antimicrobial
effect than using 0.65 µm2 graphene oxide flakes, due
to the higher defect density of smaller size graphene
particles. Interestingly, this size-dependent effect
of graphene oxide sheets on bacterial viability was
reversed when the nanomaterials were used with cell
suspensions, apparently due to the more efficient
bacterial entrapment provided by larger graphene
sheets.
Similar fundamental physical characteristics such
as sharp edges and overall negative charge seem to be
involved in broad spectrum antiviral activity of graphene oxide in pristine and reduced forms against
pseudorabies DNA virus and porcine epidemic diarrhoea RNA virus. Moreover, graphene oxide was capable of causing a structural damage to both virus types
prior to cell entry [26].
An interesting comparative toxicological analysis
study of different graphene material types has been conducted by Efremova et al [27]. They have investigated
the original graphene shells and their derivatives graphene oxide and graphene oxide paper in luminescent
E. coli reporter system addressing the nanomaterials’
toxicity and bioactivity. Of these, only graphene oxide
has shown a marked toxicity however not related to the
oxidative stress, but rather through the charge neutralisation, energy and transport pathways disruption in
3

bacteria, therefore suggesting the direct contact membrane stress and graphene oxide internalisation as the
leading mechanisms of toxicity. This report highlights
the possibility of existence of graphene-related toxicity mechanisms operating either apart or in parallel to
those included in the established paradigm of reactive
oxygen species-dependent cell damage by nanomat
erials, vindicating further studies in this direction.
However, in stark contrast to the data above,
Barbolina et al demonstrated that graphene oxide in a
highly purified form did not exert any bactericidal or
growth-enhancing effects in several strains of E. coli
and Staphylococcus aureus [28] at the concentrations
as high as 1 mg ml−1, unlike the insufficiently washed
graphene oxide samples which retained antimicrobial
activity. The authors attribute this phenomenon to the
impact of the acidic impurities on the nanomaterial
surface which can be eliminated via implementing a
strict purification protocol.
This fact once again stresses the importance of a
thorough physico-chemical assessment of the prospective nano-enabled products at each stage of their development, to avoid the misleading results concealing the
true activity spectrum of novel agents independent of
their future specific applications. On this note, among
the other most common contaminants which might
contribute to rendering false positive efficacy readouts are endotoxins and the presence of these must be
subject to scrutiny in any study addressing biological
effects of the engineered nanomaterials, including the
graphene-based [29].
Graphene nanomaterials exert their antibacterial properties not only on a wide range of pathogenic
microorganisms, but also on the bacteria present in
the environmental ecological systems. For instance,
graphene oxide has been shown to inhibit growth and
viability of Pseudomonas putida species, a common
bacteria involved in wastewater treatment process.
P. putida displayed a concentration-dependent decrease
of activity evaluated by its ability to remove the pollutant salicylic acid from simulated urban and industrial
wastewaters upon exposure to graphene [30]. Similar
and long term effects of natural and industrial carbonaceous nanomaterials, including biochar, carbon
black, multi-walled carbon nanotubes and graphene
have been registered on the bacterial and fungal communities of soil, judged by the analysis of soil biomass
accumulation and substrate-induced respiration [31].
Dose-dependent toxicity of synthesised graphene oxide
has been also recently reported against methylotrophic
yeast Pichia pastoris as a model industrial microorganism. In this case, key mechanisms suggested to be contributing in microbicide activity involved generation
of reactive oxygen species and cell membrane damage. Upregulation of genes responsible for synthesis of
unsaturated fatty acids has been identified in this study
as a key protective mechanism enabling the cells to resist
the damaging action of graphene oxide [32]. However, the database of the toxic effects of graphene and
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derivatives on the diverse bacterial representatives of
the ecosystems is fragmentary at present and requires
further significant efforts from the perspective of
increased environmental exposure to the grapheneenabled products at the end of their lifecycle.
2.2. Protozoa, algae and plants
The studies disclosing potential toxic effects of
graphene materials on this category of living organisms
are of a prime importance from the eco-toxicological
perspective, as the consequences of the exposure of the
most abundant biomass- and oxygen- producers to
damaging impacts can have very far-reaching global
consequences.
Euglena gracilis as one of the typical aquatic proto
zoan organisms has been used by Hu et al [33] as a test
model of exposure to graphene oxide ranging from
0.5 mg l−1 to 5 mg l−1 over 10 d. The authors found
that that the EC50 of graphene oxide after a 96 h long
incubation was 3.76  ±  0.74 mg l−1 and further concentration increase up to at 2.5 mg l−1 shown pronounced
and significant damaging effects on the protozoa, as
detected by growth inhibition, enhancement of malondialdehyde content and antioxidant enzyme activities.
It has been suggested that shading effect and oxidative stress could be the leading factors responsible for
observed graphene oxide toxicity. Similarly, graphene
oxide nanosheets and graphene oxide quantum dots
are able to reduce viability of another primitive freshwater organism Chlorella vulgaris. In this study it has
been shown that graphene oxide nanosheets entrap
the algae thereby reducing cell permeability, whereas
much smaller graphene oxide quantum dots induced
the shrinkage of the plasma membrane and enhanced
cell permeability with facilitated internalization effects,
plasmolysis and oxidative stress activation, leading to
the inhibition of cell proliferation and chlorophyll biosynthesis [34]. The results of this study clearly highlight
the size dependence of graphene toxicity in lower plant
species. A different species of green algae—Raphidocelis subcapitata were also prone to toxic effect of graphene oxide starting from the concentrations as low as
10 µg m l−1 [35].
In contrast to these data, it has been found that graphene oxide can in fact, exert a protective effect against
copper-induced toxicity in a primitive freshwater
plant organism microalga Scenedesmus obliquus at the
environmentally relevant concentration of 1 mg l−1 following a 12 d exposure, justifying the need for further
studies on graphene-induced effects in ecologically significant organisms of different species [36].
From a very scarce number of original reports dedicated recently to graphene toxicity in higher plants,
one can note a comparative study carried out on a
selection of plant species including Lolium multiflorum (ryegrass), Solanum lycopersicum (tomato), and
Lactuca sativa (lettuce) addressing the toxicity of the
soluble graphitic nanofibers, multiwalled carbon nanotubes and graphene oxide. The latter has been found to
4

be most toxic across the whole concentrations range,
followed by graphitic nanofibres and carbon nanotubes which were deemed relatively non-toxic [37]. In
agreement with the above, it has been demonstrated
that graphene can also suppress the morphogenesis of
rice seedlings in a concentration-dependent manner
[38] and potentiate arsenic-induced phytotoxicity in
wheat [39]. Interestingly, in the above mentioned study
[38], the lowest concentration of graphene oxide of
5 mg l−1 controversially increased adventitious root
number, fresh weight of root and over ground part of
the seedlings. The mechanism of this phenomenon has
not been disclosed and requires further investigation.
2.3. Invertebrates and lower vertebrates
A limited number of studies reported in the literature
is dedicated to the investigation of graphene effects in
a common macroinvertebrate Caenorhabditis elegans
as an alternative in vivo toxicity testing model [40].
Multi-endpoint, high-throughput study of toxicity
carried out using a panel of nanomaterials in C. elegans
has been conducted by Jung et al [41] demonstrating
that graphene was among the carbonaceous materials
clearly exerting toxic effect on this organism,
depending on the graphene oxidation state, with the
graphene oxide being most toxic, flowed by reduced
and pristine graphene. Notably, recent experiments
carried out in this model enabled to reach a new level of
understanding of the graphene-triggered toxicity and
counteracting protective mechanisms. Thus, in the
extensive genome-wide screening investigation with
quantitative analysis, 34 dysregulated long noncoding
RNAs with a potential for involvement in regulation of
various biological processes have been identified as a
result of exposure of this organism to graphene oxide.
The authors identified the shared long noncoding
RNAs, linc-37 and linc-14, involved in the control of
chemical surface modifications and genetic mutations
in alleviating graphene oxide toxicity. Furthermore,
linc-37 binding to transcriptional factor FOXO/DAF-16
might be of key importance for the control of graphene
oxide toxic impact [42]. In two reports complementing
to these findings, Zhao et al used the same model to
investigate effects of graphene oxide on C. elegans
longevity and reproductive toxicity and suggested that
the molecular mechanisms controlling graphene oxide
toxicity possibly develop via insulin signalling pathway
and through anti-apoptotic epigenetic signal encoded
protection mechanism, respectively [43, 44].
Graphene oxide is not biologically inert either for
the domestic crickets or for small aquatic vertebrates
such as zebrafish. In Acheta domesticus cricket species,
the authors studied in vivo toxicity of pure and manganese ions contaminated graphene oxide, which were
injected into the haemolymph of the insect [45] over
1–72 h interval after the administration. The results
pointed to the increased oxidative stress beyond 24 h
after graphene injection, as reflected in the elevated
activity of catalase and gluthiathione peroxidases and
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followed by raised heat shock protein HSP-70 levels.
Exposure of zebrafish to graphene oxide revealed that at
the concentration range of 1–50 mg l−1 over two weeks
there were no signs of acute toxicity despite the appearance of moderate histological changes in the liver and
intestines and clear evidence of the oxidative stress
reflected in elevated malondialdehyde levels, superoxide dismutase and catalase activities on the background
of the reduced glutathione content in the liver. Notably, in this study Chen et al for the first time have also
demonstrated that graphene oxide exposure induced
immunotoxicity in this species, as evidenced by the
raised of levels of TNF-α, IL-1β and IL-6 cytokines in
the spleen [46]. The effects of much smaller graphene
quantum dots were investigated in embryonic zebrafish
at concentrations range from 12.5 to 200.0 µg ml−1 up
and enabled to establish that the lowest graphene oxide
concentration of 12.5 µg ml−1 was relatively non-toxic
and even induced larval hyperactivity, whereas higher
doses resulted in hypoactivity and further induced
serous embryonic malformations at the concentrations
exceeding 50 µg ml−1 [47].
The comparative toxicity of different forms of graphene such as pristine graphene, graphene oxide and
reduced graphene oxide was investigated in a chicken
embryo model at the concentrations of 50–5000
µg ml−1. Interestingly, the survival rate of embryos
decreased significantly following treatment with all
types of graphene, but this phenomenon was not dosedependent. The body weights were only marginally
affected by the highest doses of graphene, whereas the
organ weights remained unaltered [48]. These findings
could be better understood in the light of the work of
Mottier et al carried out in a different model of lower
vertebrate Xenopus laevis larvae, which clearly demonstrated that the surface area in contrast to mass concentration is the most accurate descriptor of toxicity
induced by carbonaceous nanomaterials, including
graphene [49].
Overall, despite the fact that the experiments in the
invertebrates and lower vertebrates often help to unveil
fundamental mechanisms (including nanotoxicological) operating in very similar ways in the higher animals, primates and humans and are indispensable for
the development of relevant risk alleviation strategies,
they deserve far more attention in relation to the emerging graphene materials than they received to date.

3. In vitro mammalian cell and tissue
models
The studies addressing cytotoxicity of graphene
materials in cultured mammalian cell models require
a special attention in the context of this review due
to several important considerations. Firstly, they
have been and remain the most widely accepted in
vitro model systems for the baseline safety screening
and analysis of animal and human cell responses to a
diverse range of potentially hazardous agents, including
5

nanomaterials. Secondly, the majority of the cell lines
have been isolated from the human samples and
provide an excellent experimental panel for evaluating
the performance of engineered prospective diagnostic
tools and investigating the activity of new medicinal
drugs and compounds for medical devices in a safeby-design manner. Lastly, the growing number of
emerging in vitro experimental systems closely imitating
physiological exposure scenarios enables to obtain
valuable and precise information about the potential
effects of innovative diagnostic, therapeutic and
multifunctional (theranostic) tools in accordance with
the requirements of the 3Rs (Replacement, Reduction
and Refinement) approach to animal studies.
3.1. Primary and established model cell cultures
corresponding to major exposure routes
The ubiquitous presence of phagocytic cells throughout
the human body makes them a first line of defence
against any type of foreign invasions independently
of the exposure route; the engineered nanomaterials
unfortunately are not constituting a lucky exception
from the category of such invaders.
Therefore, in vitro macrophage cultures commonly
provide a staple and universal exposure model system
for evaluation of uptake, accumulation and cell functional responses assessment following the exposure to
externally presented nanoparticles. Over the last couple
of years, a growing amount of evidence has been accumulated in the literature demonstrating the ability of
graphene oxide to induce pro-inflammatory responses
in macrophages in vitro. Ma et al investigated the induction of such functional responses in phagocytes following the exposure to a panel of single-layered graphene
oxide samples with differential lateral sizes derived
from the identical starting material. They found that
large (750–1300 nm) graphene oxide flakes showed
a strong adsorption onto the plasma membrane and
reduced phagocytosis, which facilitated closer interactions with toll-like receptors and a marked activation of NF-kβ-mediated pathways. Smaller lateral size
graphene oxide sheets were more actively taken up by
cells. Consequently, larger graphene oxide particles
promoted a stronger M1 type polarization, associated
with enhanced production of inflammatory cytokines
and recruitment of immune cells, as further confirmed
in vivo by local and generalised inflammatory responses
following graphene systemic administration. Hence,
the size dependence of the phagocytic inflammatory
response to graphene oxide has been clearly elucidated
[50]. Another study conducted in RAW 264.7 macrophage cell line using carbon nanotubes, nanographite and carbon black revealed that these materials with
similar physicochemical characteristics in pristine
form or following acid treatment functionalisation
in general induced a low level of cytotoxicity. Despite
not exactly dealing with a single-layered graphene this
report deserves attention here, since it has been convincingly shown that acid functionalization enhanced
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Figure 2. Transmission electron microscopy image of pristine graphene nanosheets uptake by primary human macrophage. (A)
Graphene sheets are seen as electron-dense structures tightly packed within the lysosomal compartments of the cell. (B) High
magnification zoom on the intracellular area marked by red rectangle in (A). The details of the experimental procedure are fully
explained in [54] published by the authors of this review. Microphotographs correspond to the figure 5 of the publication, but
were not selected for the original manuscript from the repeated consistent sets of experimental data and hence were not previously
subject to copyright.

the ability of the diverse carbon materials to induce
pro-inflammatory response, except for carbon black,
as estimated by TNF-alpha production levels. Since
at the equivalent surface chemistry and exposure the
functional responses of macrophages to nanographite
were higher than those for nanotubes and carbon black,
the authors bring their data in support of the earlier
suggested platelet and fibre paradigm [51]. Unidirectional pro-inflammatory effects have been registered
by Wang et al [52] in a comparative study using multiwalled carbon nanotubes, graphene and graphene
oxide which demonstrated the increased interleukin1beta and transforming growth factor-beta1 secretion
level in phagocytic and lung epithelial cell lines THP-1
and BEAS-2B upon exposure to these nanomaterials.
Graphene oxide proved to be most potent in induction
of pro-fibrogenic response type, in contrast to pluronic
PF108-dispersed graphene and nanotubes, once again
stressing importance of the dispersal state and surface
reactivity on the ultimate outcome of the inflammatory
process in the lungs.
More complex graphene oxide-silver nanocomposites along with their pristine precursors were used
in a comparative toxicity study in murine phagocytic
J774 cell line and peritoneal macrophages from Balb/c
mice. It was found that the graphene oxide-silver nanocomposites were more toxic than the unmodified graphene oxide and silver nanoparticles in both types of
macrophages under investigation, due to significantly
higher reactive oxygen species production compared
to pristine nanomaterials [53]. The results of our own
recent studies [54] also show that pristine graphene
is readily taken up by primary human macrophages
without any significant acute functional or structural
damage (figure 2), in contrast to pristine single walled
carbon nanotubes triggering the autophagic type of cellular response.
6

A number of recent reports focussed on the toxic
responses of human cells to graphene materials
developing as a result of the potential specific exposure routes. Thus, primary human corneal epithelium
cells (hCorECs) and human conjunctiva epithelium
cells (hConECs) were implemented to investigate the
dose-and time-dependent toxicity of graphene oxide
in the case of occasional or repeated ocular exposure.
Acute 2 h long graphene oxide exposure did not induce
cytotoxicity to hCorECs in contrast to the short-term
24 h exposure causing a marked cytotoxicity both in
hCorECs and hConECs with the raised indicators of
oxidative stress in a dose-dependent manner between
12.5 and 100 µg ml−1. Of note, these findings correlate
well with the results subsequently obtained in a rat and
rabbit animal models [55].
A comparative study of cytotoxicity of graphene
oxide and pristine graphene has been carried out in the
model of skin fibroblasts which to some extent imitates
the dermal exposure scenario. It established that the
more compact graphene sheets proved to be more damaging to mammalian fibroblasts than the less densely
packed graphene oxide [56].
The enteric ingestion route has been mimicked in the
model of CaCo-2 cells. Four different graphene oxide
monolayer and aggregate samples were tested and
despite the evidence of close interaction on nanomat
erials with the cell surface and the formation of reactive
oxygen species, no visible signs of acute toxicity were
found for any of the graphene types up to 48 h exposure.
Graphene nanoplatelets aggregates induced detectable, but low toxicity at higher concentrations up to
80 µg ml−1 strongly indicating that aggregation state
and the number of graphene layers have a stronger
impact on cytotoxicity than their lateral size [57].
In respect of the systemic parenteral exposure scenario, it is essential to characterise the consequences of
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the nanomaterials encounters with the key components
of vascular system and blood. Graphene oxide has been
shown to induce damaging effects on human red blood
cells, as evidenced by the efflux of haemoglobin from
erythrocytes in suspension. At the smallest particle size,
graphene showed the strongest haemolytic activity, in
contrast to the aggregated graphene sheets [56]. On the
other hand, Chowdhury et al evaluated the interaction of
more complex structures such as graphene nanoribbons
with red blood cells, vascular endothelial cells, platelets,
monocyte/macrophage cells, mast cells and complement proteins. Although the nanoribbons induced a low
degree of concentration-dependent deformation of red
blood cells, it did not lead to haemolysis. Exposure to the
nanoribbons up to 80 µg ml−1 did not lead to any significant changes in the all the other components of the blood
vascular system under study, except for endothelial cells
which were actively taking up the graphene nanoribbons
and exhibited a concentration dependent decrease in cell
viability [18]. These data are in concert with the report
confirming the damaging effect of few-layer graphene
with lateral dimension of ~160 and thickness of ~0.8 nm
on DNA of human primary umbilical vein endothelial
cells involving an organized oxidative stress paradigm
[17]. Furthermore, graphene oxide has been also shown
to exert a particular adverse effect on B cell functions and
the humoral immunity, as confirmed by modulated B
cell surface phenotype affecting CD80, CD86 and CD40
receptors and antigen presenting molecules. The secretion of immunoglobulins by terminally differentiated
plasma cells was also markedly suppressed by graphene
oxide [58].
Mimicking the inhalation exposure conditions in
cell cultures imposes a significant level of complexity
as the closest available model of air-liquid interface has
been introduced quite recently on its own, and the data
on graphene toxicity in this model are not yet available.
In general, similar limitations imposed by the absence
of reliable and validated models adequately imitating
physiological 3D microenvironments presented by normal mammalian cells and interweaving connective tissue components currently apply to most experimental
systems implementing non-transformed cell models
and are likely to be improved in line with the future technological advances in cell and tissue culture approaches.

adipocytes, irrespective of the type of nanostructure
used [20].
Recent literature in the field also for the first time
includes a report on the cytotoxicity of graphene oxide
and reduced graphene oxide on spermatogonial stem
cells. This study showed that graphene oxide significantly increased oxidative stress at concentrations
above 100 µg ml−1, leading to the reduction of the cell
number. However, a reduced graphene treated sample
in contrast, demonstrated a significant increase in cell
proliferation [59].
Toxic effects of graphene oxides have been also
investigated in several elegant physiologically relevant
cell-free models. For example, it has been reported that
graphene oxide nanosheets can affect the ultrastructure and biophysical properties of the pulmonary surfactant film, which sheds a new light on the inhalation
toxicity potential of these materials. Upon deposition,
the graphene oxide nanosheets induced pores in the
pulmonary surfactant film thereby imposing adverse
effects on its ultrastructure and biophysical properties. Notably, the pore formation induced by graphene
nanosheets results in increasing the compressibility of
the surfactant film and associated functional inhibition
[60]. The propensity of graphene oxide to attach to and
to disrupt model cell membranes has been investigated
using supported lipid bilayers and supported vesicular layers composed of zwitterionic 1,2-dioleoyl-snglycero-3-phosphocholine. It was found that the
attachment of graphene oxide particles to supported
lipid bilayers was controlled by electrostatic interactions and the disruption of lipid vesicles. However,
when the exposure of the supported vesicular layers
to the nanoparticles was terminated, the pores on the
lipid bilayers demonstrated a remarkable self-healing
ability [61]. Potential cytotoxicity mechanism of graphene oxide was also investigated using large-scale, allatom molecular dynamics simulations to explore the
mechanism of interactions between a HIV-1 integrase
protein dimer and graphene nanosheets oxidized at different levels. The authors came to the conclusion that
the graphene nanosheet could intercalate between the
two monomers of the dimer, disrupting the protein–
protein interactions and eventually leading to dimer
disassociation [62].

3.2. Other normal mammalian cells and cell-free
systems
Among these publications, the impact of graphene
nanostructures on the functional responses of
mesenchymal stem cells (MSCs) deserves a special
attention. Thus, Talukdar et al performed a comparative
study of several 2D graphene nanostructures including
graphene nano-onions, graphene oxide nanoribbons
and graphene oxide nanoplatelets on viability
and differentiation of human MSCs and arrived
to the conclusion that despite active uptake, at the
concentrations below 50 µg ml−1 they neither affected
the cell function or MSCs differentiation potential into

4. In vivo animal models
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The reports addressing the issues of graphene toxicity
in vivo in the laboratory animals can be analysed best
from the angle of relevant exposure routes similarly to
the above discussed in vitro systems, as this approach
provides a more systematic information for the risk
assessment process.
4.1. Respiratory exposure route
One of the most likely exposure scenarios potentially
applicable both to the industrial manufacturing
settings and for accidental environmental presentation
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of graphene to humans is the respiratory (inhalation)
route.
Han et al [63] investigated effects of graphene
oxide on the lungs of Sprague-Dawley rats in a single
6 h nasal inhalation technique at 0.46 and 3.76 mg m−3.
They found that the exposure to graphene material
did not cause any major changes in the body or organ
weight and food consumption during the two weeks of
recovery interval. Similarly, neither microalbumin nor
lactate dehydrogenase content in the bronchoalveolar
lavage fluid shown any significant changes. Same applied
for total cell count and the number of macrophages,
neutrophils and lymphocytes. Histologically, clear
uptake of graphene oxide by the alveolar macrophages
was detected only after exposure to the higher concentration. In a very close experimental system implementing nasal inhalation exposure in rats, but over a more
lengthy period of 28 d and using the graphene oxide
concentrations of 0.12, 0.47, and 1.88 mg m−3 followed
by up to three months-long recovery, no gross body or
organ mass changes were registered either. Despite the
fact that the nanomaterial has been actively taken up by
phagocytes and accumulated further in lymph nodes,
no significant pathological alterations were observed
in the lungs of the exposed rats [64]. Overall, these data
witness a minimal level of graphene oxide pulmonary
toxicity either after a single or multiple dose extended
inhalation exposure even at the relatively high concentration which likely exceeds the potential realistic
environmental equivalent.
In an alternative intratracheal instillation model,
potential pro-inflammatory effects of graphene nanoplatelets and their accumulation in the mediastinal
lymph nodes of rats has been addressed in the context
of varying surface functionalisation of nanomaterial
by COOH groups. All the tested graphene particles,
whether in the original pristine form or decorated
with COOH functional groups, demonstrated a high
ability to induce generation of reactive oxygen species.
In this work, both acute and chronic inflammogenic
effects have been analysed after 24 h with the instilled
doses of 0.3 and 1 mg/rat and following 1 and 4 weeks at
3 mg/rat dose. Interestingly, only the positively charged
graphene nanoplatelets demonstrated a significant
increase of neutrophil counts after 24 h, despite the
fact that unidirectional dose-dependent effects were
noticeable with all the particle types under study. The
observed acute pro-inflammatory effect was not sustained and cell counts returned to normal already after
1 week. However, there was a progressive accumulation
of nanomaterial in the regional lymph nodes over time,
irrespective of its surface charge modification [65].
Pulmonary and systemic toxicity of different size
graphite nanoplateles has been comparatively analysed
by Roberts et al [66] in mice after pharyngeal aspiration followed at 4 d to 2 months post exposure. Despite
the varying lateral (2–20 µm) dimensions and thickness (8–25 nm) of nanoplatelet samples, at the dose
of 4 µg/animal no signs of toxicity were registered.
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However, the exposure of mice to 40.0 µg of graphite
nanoplatelets with 5.0 and 20.0 µm lateral dimensions
lead to the pulmonary inflammation and altered tissue
gene expression profile in the lungs, aorta and hepatic
inflammatory and acute phase genes. Biodistribution and toxicity of radiolabelled graphene, following a similar intratracheal instillation model as above,
has also been monitored in mice after up to 4 weeks
post exposure. In this quantitative study, it was found
that about half of the instilled graphene dose has been
excreted through the gastrointestinal tract and in spite
of the fact that about the same amount was persistently
retained in the lungs even after 4 weeks, it caused only
a transient dose-dependent pulmonary inflammation
and oedema. Interestingly, minor amounts of graphene
(up to 1%) bypassed the alveolo-capillary barrier and
were deposited in the liver and spleen [67].
It is important to stress here that in several related
studies discussed above the authors used different ways
to estimate the exposure dose (e.g. weight by volume
and dose per animal), which complicates the direct
comparison of the achieved experimental results,
clearly strengthening the pressing need on the researchers in the area to reach an agreement on a long-awaited
unified approach to dose-exposure calculations in
nanotoxicology studies, including those involving graphene-based materials.
4.2. Systemic parenteral exposure
The investigations into the possible manifestations
of toxicity following this particular exposure route is
of a paramount importance for the development of
innovative diagnostic imaging probes, therapeutic
and multifunctional theranostic nanodrugs alike
containing graphene in any form.
An earlier report by Wang et al addressed the issue
of acute and chronic dose-dependent toxicity of graphene oxide in mice after systemic intravenous administration. In doses up to 0.25 mg per animal no signs
of acute or chronic toxicity were detected. However,
the high dose of 0.4 mg per animal (~20 mg kg−1) lead
to the accumulation of graphene in the lungs, liver,
spleen and kidneys as a result of insufficient clearance,
along with the chronic toxicity manifestations, such
as lung granuloma formation [68]. In a similar study
and equivalent high doses of 20 mg kg−1, pristine few
layered graphene and its carboxyl- and PEG-modified
forms were predominantly retained in the same organs
with no accumulation in the brain, heart or testes after a
3 month monitoring. Irrespective of the surface chemistry, graphene materials accumulation in the organs
led to the notable cellular and organ damage manifesting in appearance of necrotic and fibrotic foci as well as
glomerular filtration dysfunction [69].
More recently, similar results have been obtained
using the intravenously injected graphene oxide, in this
case functionalized with poly sodium 4-styrenesulfonate. Graphene material accumulated in the lungs,
liver and spleen, was retained in these organ locations
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for over 6 months and induced clear systemic signs of
chronic organ-specific inflammation [70]. In contrast,
reduced graphene oxide following intravenous injection in rats at a dose of 7 mg kg−1 (comparable to the
study above if recalculated to an average rat weight)
did not induce any significant changes in haematological, histopathological, liver- and kidney-specific
biochemical tests and genotoxicity indicators 7 d post
treatment. Transient fluctuations in the blood leukocyte counts and increased superoxide dismutase activity were the only parameters moderately altered by
reduced graphene exposure [71]. A more complex form
of graphene such as manganese-intercalated graphene
nanoparticles functionalized with dextran intended for
the use as magnetic resonance (MRI) contrast imaging agent injected 3 times a week over 3 weeks has been
investigated along the lines of dose-dependent subacute
toxicity in rats. It has been established that the systemically administered doses not exceeding 50 mg kg−1 of
this graphene formulation could be safely used as MRI
diagnostic probes [72]. The findings of such extended
studies are of prime importance to the development of
graphene-enabled nanomedicinal products intended
for systemic use, as the results of short-term invest
igations of graphene oxide biodistribution [73] can
possibly lead to overoptimistic interpretations based
on the absence of acute toxic effects.
A different, intraperitoneal parenteral administration route has been used by Kurantowicz et al in their
comparative investigation of biodistribution of a range
of carbonaceous nanomaterials, including graphite and
graphene oxide in Wistar rats. The nanomaterials in the
form of large aggregates were detected at the injection
site as well as in the gastric serous membrane, within the
connective tissue of the abdominal skin, muscles and
peritoneum. Small aggregates of graphite and graphene
oxide nanoparticles were observed in the mesentery
and in the connective and lipid tissues near the liver and
spleen serosa. None of the tested nanoparticles affected
any key blood parameters or growth of rats even at
4 mg kg−1 dose injected 8 times over 4 weeks [74]. In
contrast, a comparative study performed in BALB/c
mice using intraperitoneally injected pristine graphene,
graphene oxide and single wall carbon nanotubes at
the equivalent dose of 4 mg kg−1 over 7 d revealed the
increased levels of malondialdehyde and reactive oxygen species and associated morphological damage signs
in kidneys and brains of the exposed animals, with the
pristine graphene being less toxic than other carbonaceous nanomaterials under investigation [75].
However, despite being important observations
from the mechanistic and experimental perspective,
this delivery route is one of the least likely to be implemented in humans.
4.3. Enteric route
The consequences of oral administration of graphene
oxide have been studied in Sprague-Dawley rats
at the doses of 10–40 mg kg −1 [76]. The results
9

demonstrated the increased activities of superoxide
dismutase, catalase and glutathione peroxidase in
a dose-dependent manner in the rat kidneys, along
with the significantly elevated serum creatinine,
blood urea levels and enhanced accumulation of
hydrogen peroxide and lipid hydro peroxide. Altogether,
this is a clear indication of the oxidative stress-mediated
in vivo nephrotoxicity in experimental animals
justifying further in-depth studies in this direction.
Ingestion of reduced graphene oxide by mice has also
led to transient changes in behavioural activity of the
animals, such as general locomotory activity, sense of
balance and neuromuscular coordination, which the
authors attribute to the possible influence of reduced
graphene oxide exposure on the activity of serum
superoxide dismutase. In contrast, only little change
in exploratory, anxiety type, learning or memory
behaviours has been noted [77]. Unfortunately, from
these reports it is hard to provide direct extrapolations
to the potentially envisaged exposure doses either
from the human occupational or consumer products’
perspective.
An important study for the first time has been
conducted to establish the effects of daily intragastric
administration of multi-layered pristine graphene
into mice over 4 weeks. In the view of the antibacterial activity of graphene materials discussed earlier in
this review, it was very interesting to see that graphene
exposure actually increased biodiversity of gut microbiota and changed the microbial community in favour
of G-bacteria, possibly due to the selective sensitivity
of different microorganisms to oxidative stress and
their ability to maintain cell membrane integrity following contact with graphene. As a matter of serious
concern, graphene exposure also significantly increased
the abundance and types of antibiotic resistance genes
in murine gut microbiota [78]. These findings must
be undoubtedly taken into account in the design of
the new drugs containing graphene intended for oral
administration and we can expect more vital discoveries in this field in the future.
4.4. Transcutaneous (dermal) exposure
A growing number of recent publications suggests the
use of graphene-based materials in innovative dermally
applied sensors, diagnostic and transcutaneous
drug delivery devices, skin tissue engineering and
regenerative systems [8, 79–84]. Despite the fact that
carbonaceous nanomaterials in general, are well known
to be associated with the increased incidence of various
skin diseases, such as dermatitis, hyperkeratosis, naevi,
excessive sensitization and other conditions [85–87],
a surprisingly limited number of studies actually
addressed the effects of graphene on the dermal toxicity
and the functional state of its cellular components
in vivo.
Among these, there is a single report that graphene oxide-incorporating antibacterial cotton fabrics, despite being over 90% lethal to bacteria even
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after a hundred washes, caused no irritation to rabbit
skin [88].
The studies on the effects of graphene and its derivatives, such as for example PEGylated graphene oxide/
polypropylene fumarate nanocomposites on one of
the key cellular skin components - dermal fibroblasts
have been done so far only in in vitro systems [56, 89].
In both reports, graphene was found to be non-toxic
to fibroblasts. In contrast to these, Wang et al [68]
demonstrated that graphene oxide can actually
induce decreased adhesion, cytotoxicity and apoptosis
of human fibroblasts at the concentrations over
50 µg ml−1.
Altogether, this exposure scenario remains largely
underexplored and taking into account controversial
available experimental evidence, requires further indepth investigations.

5. Biological mechanisms affecting
grahene toxicity at the cellular
and organismal level
5.1. Biomolecular corona and protein adsorption
One of the fundamental factors strongly influencing
the nanomaterials’ biocompatibility irrespective of
their ex-synthesis composition is the formation of the
so-called ‘biocorona’ occurring upon their contact
with the biological milieu containing a wide range of
biomolecules, including an abundant array of proteins
[90–92]. Since the original term ‘protein corona’
has been coined nearly a decade ago, multiple reports
have established its significance for the functional
behaviour of nanoparticles and their resulting effects
at the cellular and organismal level. Depending on the
size, nanoparticles can be either surrounded by the
biocorona (in its classical interpretation) or themselves
deposit as intercalating ‘nano-glitter’ [93] on the surface
of the interacting biomolecules or within the folded
protein structures at the sites where the active physicochemical parameters and factors including size, charge,
hydrophobicity/hydrophilicity, available chemical
groups and bonds favour such interactions [94].
On the other hand, the dynamic composition of
the biocorona can be also actively influenced by the
introduction of the surface-modifying agents deposited as additional layers over the nanoparticle core.
Notably, an example of surface modification resulting
in the improved in vitro and in vivo biocompatibility of
graphene oxide was identified using poly(acrylic acid)
functionalization. Cytotoxicity, platelet depletion, proinflammatory responses and pathological changes in
lungs and liver of mice typically induced by graphene
oxides were efficiently alleviated by this surface modification in comparison to the pristine or PEGylated
graphene oxide nanomaterials both in in vitro and in
vivo tests. Such pronounced effects are explained by
the authors as likely to be due to the differential compositions of protein corona, especially immunoglobulin G, forming on the surface of nanoparticles and
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governing their cell membrane interactions and cellular uptake, the extent of platelet depletion in blood,
thrombus formation under short-term exposure and
the known pro-inflammatory effects after long-term
exposure [95]. These data are in concert with the findings illustrating that BSA protein coating can mitigate
the cytotoxicity of graphene oxide by reducing its cell
membrane penetration via weakening the interaction
between the phospholipids and graphene surface due
to a reduction of the available surface area and unfavourable steric effects, thereby significantly reducing
the graphene membrane penetration and associated
lipid bilayer damaging [96]. Similarly, a strong protein
adsorption through π–π stacking interactions between
graphene oxide and aromatic protein residues in addition to hydrophobic interactions was established in
a simulation-based molecular dynamics approach.
This highlighted a hypothetic potential for reduced
cytotoxicity of graphene oxide and reduced graphene
oxide nanosheets following their coating with major
high abundance blood proteins, which has been subsequently experimentally confirmed [52, 97].
However, the question of the definitive effect of
the biocorona as a function of its composition on the
graphene toxicity remains not fully understood and
a subject of controversy. Thus, the opportunities for
the reduction of graphene oxide nano-sheets toxicity
have been also addressed in the context of the potential
biocorona-contributing secreted compounds found
in zebrafish culture water, such as small organic molecules, proteins, nucleotides and mucopolysaccharides.
However, in this case the complexes of these biological
secretions with graphene displayed a modified nanoplateles topography with thicknesses of about 10 nm
and lateral lengths ranging from 19.5 to 282 nm exhibiting a more negative surface charge, lower aggregation
state and higher toxicity resulting in death, congenital
malformations, upregulation of beta-galactosidase and
loss in mitochondrial membrane potential of zebrafish
embryos [98].
5.2. Biodegradation, catabolic pathways
and clearance
Since the first encouraging report by Kagan et al in
2010 [99] on the possibility of carbon nanotubes
catalytic degradation in vitro and in vivo by neutrophil
myeloperoxidase, an intriguing question now is
whether the same phenomenon is applicable to a range
of other carbonaceous nanomaterial representatives,
including graphene in the focus of this review. If yes, it
might constitute a valid approach to mitigation of longterm toxicity due to the nanomaterial accumulation,
as an efficient elimination mechanism in combination
with other biologically important factors, such
as ‘coronation’ with proteins, lipids, and other
biomolecules affecting the enzymatic degradation
process, as just reviewed in [100].
The uptake and potential signs of degradation of
carbonaceous nanomaterials, including graphene
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Figure 3. Pristine graphene uptake by phagocytes analysed by Raman spectroscopy. (A) Transmitted light image of primary human
macrophages exposed to pristine graphene flakes. (B) The microscopic field selected for Raman mapping. (C) G-band (~1580 cm−1)
Raman mapping over the selected cell area, full width at half maximum (FWHM) measurement. (D) A representative Raman
spectrum of graphene within the macrophage. The presence of D-band (~1350 cm−1) in graphene can serve as an indicator of the
appearance of disordered structure and hence possible biodegradation. The details of the experimental procedure are fully explained
in [54] published by the authors of this review. The illustrations correspond to the figure 10 of the publication, but were not
selected for the original manuscript from the repeated consistent sets of experimental data and hence were not previously subject to
copyright.

within the cells can be can be analysed in a very specific
quantitative manner by Raman spectroscopy (figure 3),
as the appearance of a D-band (~1350−1) can serve as
an indicator of the material structural disintegration
and biodegradation potential [69, 101].
Catabolic degradation routes triggered in phagocytes after carbonaceous nanomaterials exposure have
been very recently addressed by McIntyre et al [54]. The
authors compared the catabolic processes induced in
primary human macrophages by pristine graphene and
pristine single walled carbon nanotubes, both with similar surface chemistries but different geometries. It was
shown that the PG did not behave like any of its derivatives, it was phagocytosed by the primary macrophages
in abundance, did not induce autophagy and was not
degraded following 24 h accumulation within these
cells. Of an important note, graphene oxide in contrast to the above observation with pristine graphene,
has been shown to be more prone to induction of the
autophagic type of protective anti-toxic response in
human-hamster hybrid mammalian cells against polychlorinated biphenyls, acting as their potential adsorbent due to its large surface area and high abundance of
oxygen-containing functional groups [102].
This makes us put a strong note that despite the fact
that biodegradation of graphene and graphene-based
products is an important and potentially exploitable
pathway of alleviating the toxicity of these nanomat
erials, it must be kept in mind that the biodegradation
process per se can result on the formation of more
11

chemically aggressive derivatives possessing strong
adverse effects on the normal body cells and tissues.
The recent overview by Vlasova et al [103] witnesses
that a plethora of diverse oxidative enzymes present in
inflammatory cells, such as myeloperoxidase, peroxidase of eosinophils, lactoperoxidase, xanthine oxidase
and haemoglobin, all of which can contribute to the
biodegradation of nanomaterials. Such widespread oxidative machinery applied to graphene can in principle
cause the formation of the oxidized species with even
more pronounced toxic characteristics than those of the
original nanomaterial [104].
The issue of a paramount importance related to the
nanomaterials with limited or not fully identified biodegradation pathways is the degree of biopersistence
and clearance of these materials from the organism
following the exposure resulting in systemic distribution. On one hand, it is dictated by the size of the
nanoparticle in question which must not exceed the
filtration threshold of the kidney barrier of 10–12 nm
[105, 106] and should be not subject to increase due to
the aggregation prior to reaching the filtration barrier.
Two recent studies carried out by Jasim et al addressing
the biodistribution and urinary clearance of graphene
oxide sheets of different thickness following systemic
intravenous injection [73, 107], demonstrated that even
with the lateral dimensions falling in the micrometre
range, graphene oxide materials with an average thickness of 2–10 nm can still successfully pass though the
murine kidney filtration barrier, therefore apparently
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lending themselves to convoluted geometrical shape
adaptations under the physical shear forces involved in
the process. Nonetheless, the report by Sasidharan et al
[69] denies any appreciable renal clearance of few layer
pristine graphene or its carboxylated and PEGylated
derivatives even of the much smaller average thickness
of 0.8–1.3 nm and lateral dimensions of 115–160 nm,
leaving the issue of clearance of graphene materials via
renal filtration a subject of controversy. On the other
hand, the efficiency of the clearance is also dramatically
affected by the thickness- and surface functionalisation-dependent graphene nanoparticles retention in
the cells of the reticuloendothelial system of the parenchymatous organs such as spleen and liver [107] and/
or associated secondary inflammatory effects in other
organs, e.g. lungs [66]. As a result, the success on the
front of construction of clearable carbonaceous nanomaterials in general and graphene-enabled medicinal
products in particular, is so far very limited, with just
a few publications reporting such possibility [73, 107,
108–110], therefore justifying further expanded invest
igations into this field.

6. Approaches to toxicity mitigation
and safe-by-design development of
graphene-enabled products
6.1. Risk assessment strategies
The introduction of graphene-enabled products
(GEP) into the market has to be appropriately assessed
in terms of the associated risks and uncertainties at
macro-, micro- and nano-scale level. In particular,
before novel materials and products will be placed
on the market it is crucial to minimise potential risks
regarding development costs as well as regulatory needs
and environmental concerns (i.e. health and safety
aspects).
Since graphene as advanced material lends itself to
a large variety of different applications, it provides a
challenge for assessing their risks and associated safety
for consumer, occupational workers and the environ
ment. Furthermore, as presented above, depending
on the end-use application GEP can have many physicochemical property differences. Therefore GEP risk
assessment can be extremely demanding if for each
product resources and time have to be committed in
a case-by-case basis. Therefore, most of the scientific,
industrial and regulatory drive in the past 10 years
has been focused on developing suitable characterisation cascade, quality assurance tools and frameworks
for risk assessments, management and monitoring of
emerging products containing advanced materials. In
most of the cases the enhancement is associated with a
nanoscale property of the materials in use [111].
The introduction of a tiered safe-by-design
approach [112] can provide a de-risking strategy
towards the identification of uncertainties and risks
from the early developmental stages of GEP. Standardisation of graphene characterisation is also an i mportant
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aspect towards the increased consumer confidence,
reproducibility, and quality assurance of various types
and formulations of carbon products. Furthermore, the
introduction of safety thresholds of each components
of the GEP will allow for a prioritisation in the risk
assessment process. There highest health risks are the
first to be screened and this is where the most important
information is acquired and assessed. Such approach
therefore allows for the creation of nano-specific risk
assessment strategy, as proposed recently by Dekkers
et al [113] which can be applied across the different
industries for the benefit of the consumer, and in the
case of medical products, for the patients.
6.2. Selecting the optimal physicochemical
characteristics
Several important considerations must be taken
into account when attempting to reduce the toxicity
associated with exposure to GEP and to implement
appropriate risk mitigation measures. Such
fundamental physical characteristics as size [56, 114],
shape and geometry [18, 20, 27], charge [26, 27, 56]
and dispersion/aggregation state [37, 66, 115], can be
effectively used to identify and exploit the optimally
performing graphene-based systems and devices for a
particular intended application with minimal healthdeteriorating side effects. A significant impact can be
also imposed by the difference in the toxicity potential of
pristine, oxidised and reduced forms of graphene, with
less oxidized graphene reported to produce higher levels
of reactive oxygen species, cytotoxicity and apoptosis
[104]. Among the most recent and appealing findings,
we must also mention the opportunity to exploit chiral
properties of graphene quantum dots. The exposure of
liver HepG2 cells to the L/D-cysteine moieties attached
to the edges of graphene quantum dots revealed their
general biocompatibility and a noticeable difference in
the toxicity of such stereoisomers [116].
6.3. Surface modification by chemical
functionalisation
Among the earlier reported simple approaches to
reduce damaging effect of graphene oxide on red blood
cells, the coating with chitosan has been demonstrated
as a nearly 100 percent efficient way for elimination of
this type of toxicity [56]. A pluronic block copolymer
in complex with graphene oxide has been shown to
significantly reduce the toxicity of graphene oxide in
human fibroblasts and demonstrated the potential of
this approach for everyday life bacterial disinfection
applications, as hypotonic pluronic and graphene oxide
mixture proved to be both safe and effective [52, 117].
In one of the most recent studies a new unique
hydroxylated graphene derivative has been shown to
provide a beneficial environment for cell adhesion
and growth of rat adipose tissue-derived stromal cells
due to its hydrophilicity and weak inductive nature.
Of note, the overall simplicity of this approach enables to produce such graphene derivative in i ndustrial
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kilogram-scale amounts [84]. Graphene nanoplatelets surface-modified with polyvinyl acetate rendered them non-toxic at the concentrations of up to
50 mg ml−1 compared to pristine nanoplatelets in
HFF-1 cells model [118]. Amine-modified graphene
oxide has been proven to be a much safer functionalised
material in terms of the potential thrombogenic and
haemolytic effects in mice in vivo in comparison to its
unmodified graphene oxide or reduced graphene oxide
counterparts [119].
6.4. Other exploitable environmental
and biological factors
Humic acid as a natural organic matter has been found
to be an effective graphene oxide toxicity alleviation
agent in E. coli aqueous bacterial model. This natural
agent exhibited an antioxidant action role, maintaining
the activity of the antioxidant enzymes and decreasing
the reactive oxygen species generation, as witnessed
by the results of oxidative stress experiments, thereby
having important ecotoxicology implications [120].
A very appealing observation from the microbiological point of view has been made by Zhao et al who
have found that the pre-treatment with the established
famous probiotic Lactobacillus bulgaricus prevented
graphene oxide toxic effects on the functions of both
primary and secondary targeted organs in wild-type
nematodes Caenorhabditis elegans and reduced graphene oxide damage in nematodes with mutations of
susceptible genes (sod-2, sod-3, gas-1, and aak-2) by
sustaining normal intestinal permeability. L. bulgaricus also sustained the normal defecation patterns in
both wild-type nematodes and those with mutations
of susceptible genes. The beneficial role of L. bulgaricus
against graphene toxicity is explained by the authors as
due to the combinational effects on intestinal permeability and defecation behaviour. Interestingly, the beneficial effect of L. bulgaricus on graphene toxicity was
dependent on the function of acs-22 gene homologous
to mammalian fatp4 encoding the fatty acid transport
protein 4. This study, despite been carried out in worms,
might pave the way towards innovative pharmacological strategies to protect a natural intestinal barrier from
the graphene oxide toxicity in higher species [121].
Another novel and attractive ‘all-biological’
approach for assembling water-soluble and cellcompatible graphene oxide has been offered using
Ginkgo biloba extract as a reducing and stabilizing agent, resulting in the overall lower toxicity and
increased biocompatibility of the complex [122].
6.5. Facilitated degradation
The rationally designed graphene oxide nanocarriers
modified with polyethylene glycol and branched
polyethylenimine have been introduced to control
the biological activity of oxidised graphene as a
nanodrug carrier and its degradation in biological
systems. Such nanostructures efficiently interact with
plasmid DNA forming a stable nanocomplex via
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electrostatic interactions. Following the uptake by the
cells, the complex can readily escape from endosomes
by photothermal conversion of graphene oxide upon
near-infrared irradiation and photothermally induced
endosome disruption. As a result, reducing intracellular
environment enables polymer dissociation and rapid
gene release with enhanced transfection efficiency and
decreased toxicity in comparison to non-reducible
amide-functionalized graphene nanocarriers.
In addition, the de-PEGylated graphene oxide
nanocarriers exhibit higher engulfment by phagocytes
due to their exposed disulfide bonds, and are subject
to subsequent facilitated degradation in macrophages
[123]. An innovative approach was developed by Zan
et al to fabrication of water-dispersible nanocomposites
with iron oxide nanoparticles attached to graphene,
enabling to produce biocompatible and apparently
biodegradable structures intended as potential sensitive
T2 contrast agents. The authors claim that these
composites can be cleared from the body through the
metabolic processes and therefore are harmless to the
living organism [124]. However, as the biodegradation
process in this case was related only to the iron oxide
component of the complex, this study reinforces
the importance of implementation of the above
mentioned safe-by-design approach [113], which
must be strictly adhered to from the very early stages
of the new nanomedicines development in relation
to all the constituent components. It ensures that the
new diagnostic and therapeutic preparations are safe,
have maximal possible specific efficiency with minimal
impact on the normal cells and therefore can eventually
find their approved clinical applications and earn the
deserved space on the pharmacy shelves.

7. Emerging opportunities for biomedical
applications
7.1. Graphene-enabled products as bactericidal
agents
In the general context of potential graphene toxicity to
living biological systems, the established toxic effects
displayed against pathogenic bacteria discussed above
could constitute a desirable and exploitable property.
However, overall the bactericidal activity of pristine
graphene and graphene oxide materials is known to
be relatively low, which in the view of potential human
exposure significantly reduces benefit-to-risk ratio.
Hence, most recent reports have been largely focussed
on investigation of graphene-based nanomaterials
with various surface functionalities or in the form of
composites enabling to boost the antimicrobial efficacy.
Graphene oxide in a nanocomposite complex with
silver has demonstrated a remarkable bactericidal activity to some of the most common hospital contaminants
including Acinetobacter baumannii, Enterococcus faecalis, and E. coli and even to such a notorious strain as
methicillin-resistant S. aureus (MRSA) [125]. A relatively short 4 h exposure to graphene-Ag nanoparticles
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lead to a complete growth suppression of pathogenic
bacteria via a direct contact mechanism, compared to
the graphene oxide or silver nanoparticles alone. In a
related study, a systematic analysis of antimicrobial
activity of several graphene and heavy metal nanoderivatives such as graphene oxide nanosheets, Ag and
Cu nanoparticles and their nanocomposite combinations against E. coli, Pseudomonas aeruginosa, S. aureus,
Klebsiella pneumoniae and methicillin-resistant S.
aureus has been carried out. Graphene oxide in a composite with Cu and Ag displayed a clearly enhanced
wide spectrum bactericidal effect, however to a lower
extent detectable in MRSA [126].
An innovative route to increase the antibacterial
effects of graphene oxide has been demonstrated by
Buccheri et al [127]. This group used laser irradiation to
attenuate the targeted properties of this nanomaterial.
Antibacterial properties of laser radiation-modified
graphene oxide investigated in E. coli have been found
to be higher for graphene oxide irradiated for over 3 h,
which led to the reduction of the nanographene flakes
size whilst retaining a significant oxygen content and
hydrophilic properties of the material. Bacterial cell
walls shown a marked degree of damage following
the exposure to the irradiation-modified graphene
oxide. In the same study, the authors carried out tests in
zebrafish embryos and came to the conclusion that that
neither mortality nor sublethal effects were induced by
laser-irradiated graphene oxide flakes in the concentrations of up to four times exceeding those which were
found effective in lowering the bacterial growth.
A more generalised approach to increase the above
mentioned benefit-to-risk value of graphene oxide has
been offered by Karahan et al [117]. They used an abrupt
change in the environmental salinity or water shock
treatment of bacteria with a subsequent treatment with
the complexes of graphene oxide and pluronic F-127
block copolymer known for its good biocompatibility
characteristics. As a result, in under 3 h nearly 100% of
the bacteria with compromised cell walls exposed to such
nanocomplexes were killed, compared to under 30%
bactericidal efficiency registered without such treatment.
Pluronic-graphene complexes at the same time displayed
a reduced toxic effect on normal human fibroblasts.
An example of a thorough systematic approach
to investigation of biological effects of more complex
graphene derivatives on microorganisms as a function
of their structural and functional properties has been
shown by Diez-Pascual and Diez-Vicente [89]. In this
report incorporating an extensive physicochemical
characterisation of a nanocomposite material based
on the PEGylated graphene oxide and polypropylene fumarate, the authors evaluated the microbicide
efficiency of nanocomposites against several types of
G-positive and G-negative bacteria, such as S. aureus,
Staphylococcus epidermidis, P. aeruginosa and E. coli.
They have found a remarkable degree of antimicrobial
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activity of graphene oxide-based composites which was
developing in a dose-dependent manner with increasing concentrations of graphene. Of note, the authors
found that G-positive bacteria responded in a more
pronounced manner to such treatment. Despite being
important phenomenological observations, the specific
mechanisms affecting the sensitivity of diverse bacterial
types to graphene exposure apart from the presence or
absence of outer membrane are yet to be disclosed.
7.2. Graphene-enabled products for cancer
treatment
Cancer, as a disease of a prime socioeconomic
importance, has been attracting the efforts of
researchers working with advanced nanomaterials for
a number of years. This is not surprising firstly because
the arsenal of available treatment strategies is still very
limited and none of the currently available medications
can guarantee a complete cure without the serious side
effects. Secondly and partially due to the above, the
pathway for the regulatory approval of new anti-cancer
drugs could be faster and more straightforward than
in application to other diseases. Thirdly, nanomaterials
possess a number of unique properties bringing them
to the forefront of potential cancer diagnostics and drug
delivery systems, such as the opportunity to exploit the
EPR (enhanced permeability and retention) effect
[128, 129] attributed to tumours, capability to deliver
a high localised drug load and theranostic multifunctionality. Applied to the malignant cells, the term
‘cytotoxicity’ largely acquires the meaning of ‘anticancer activity’ and constitutes a desired effect. In an
ideal case scenario, the new nanomaterial intended
for cancer treatment should be cytotoxic to malignant
cells and exert minimal or no effect on the surrounding
normal cells and tissues. Unfortunately, such material ex
synthesis does not yet exist and therefore the search for the
appropriate surface functionalisation of nanomaterials
enabling to ensure such selectivity continues worldwide.
Over the last few years, several promising graphenebased nanotools have been developed and demonstrated
a strong potential for cancer therapy applications.
Thus, the exposure to graphene oxide and reduced
graphene oxide produced using uric acid (UA-rGO)
resulted in a dose-dependent decrease in cell viability
and induced cytotoxicity in human ovarian cancer
cells. The results of this study indicate that UA-rGO
could trigger apoptotic mechanisms in malignant
cells. The anti-cancer cytotoxic effects of UA-rGO were
significantly higher than those of the graphene oxide
and involved increasing lactate dehydrogenase (LDH)
release, reactive oxygen species generation, activation of
caspase-3, and DNA fragmentation [130].
Graphene oxide and its derivatives dodecylamine
graphene oxide, reduced graphene oxide and sodium
dodecyl sulfate graphene oxide displayed a strong
cytotoxic activity against the cells of a human lung
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carcinoma line A549 in a concentration-dependent
manner starting with moderate effect at 3–25 µg ml−1
and reaching a dramatic cell viability reduction at
50–400 µg ml−1 [131]. In another approach, a complex original hybrid nanostructure comprising graphene oxide and Zn-clinoptilolite as a potential drug
carrier has been explored in the same cancer cell line
A549 for its biocompatibility and it has been shown that
this construct possessed low baseline toxicity and high
anticancer drug doxorubicin loading capacity, making
it a potentially good drug nanocarrier candidate [132].
An innovative system comprising hollow magnetic
nanospheres coated with the silica shells and conjugated with carboxylated graphene quantum dots as a
core-shell composite has been offered for multimodal
cancer treatment. The composite was further loaded
with doxorubicin and stabilized with liposomes. This
multimodal system was able to destroy cancer cells
by four different therapeutic mechanisms in a synergetic and multilateral fashion, namely, the magnetic
field-mediated mechanical stimulation, photothermal
damage, photodynamic toxicity and chemotherapy.
The registered combined effect was dramatically higher
than any of those attributed to the individual comp
onent therapeutic modalities [133].
Graphene oxide functionalized with urease B as
the model antigen has been recently implemented
as a vaccine adjuvant for immunotherapy acting as a
positive modulator to promote maturation of dendritic
cells and to enhance their cytokine secretion through
the activation of multiple toll-like receptor pathways
while showing low toxicity. Further in vivo studies confirmed that this engineered graphene oxide derivative
was more efficient than free urease B or clinically used
aluminum-adjuvant-based vaccine in induction of cellular immunity, suggesting its promising potential for
cancer immunotherapy [134].
In a comparative investigation by Piper et al of graphene oxide containing variable redox-active groups
on the surface, including manganese ions, C-centered
radicals and endoperoxides, the latter were found to be
the most potent in generating reactive oxygen species
and associated toxicity in cultured human cervical cancer cells [135].
A new range of exciting opportunities in the area
of cancer treatment has been offered by the report by
Fiorillo et al [136] who convincingly demonstrated in
the advanced tumour spheroid models that graphene
oxide could be utilised for cytotoxic targeting of cancer
stem cells of different types, including some of the most
notorious malignant tumours such as pancreatic cancer and glioblastoma. Remarkably, the authors made
a significant departure from the phenomenological
observations, providing an insight into the mechanistic elements of the findings and identifying Wnt,
Notch and STAT-mediated signalling pathways as key
contributors into the induction of cancer stem cells differentiation, paving the way to the development of new
selective anti-cancer nanomedicines.
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7.3. Advanced multimodal medical applications
of polyfunctional graphene derivatives
A series of recent publications addresses the measures
for improved biocompatibility and lowered toxicity
using more complex functionalisations of graphene,
which is of a particular importance for the prospective
diagnostic imaging, therapeutic and multimodal
theranostic tools. For example, indocyanine greenloaded polydopamine-reduced graphene oxide
nanocomposites with amplifying photoacoustic and
photothermal effects enabled to achieve a complete
suppression of tumors in 4T1 breast subcutaneous
and orthotopic mice models after photoacoustic
imaging-guided photothermal treatment, with
no signs of accompanying systemic toxicity [137].
A similar approach using indocyanine green conjugated
with PEGylated reduced graphene oxide has been
implemented for photoacoustic and fluorescence dualmodality tumour imaging in vivo in mice. The resulting
nanocomposites had minimal toxicity and superior
passive tumour targeting with steady photoacoustic
and fluorescence signals sustained over 6 h post
systemic intravenous injection [138].
Luo et al have constructed a related poly-
functional nanosystem integrating the photodynamic
and photothermal therapy for cancer treatment.
In their approach, a photosensitizer IR-808) with cancer-targeting ability and near-infrared sensitivity was
chemically conjugated to both polyethylene glycoland branched polyethylenimine-functionalized graphene oxide nanoparticles. A significantly enhanced
photodynamic and photothermal therapy effects were
achieved both in murine and human cancer cell models
apparently facilitated by the preferential accumulation
of the nanocomplexes by cancer cells mediated by the
organic-anion transporting polypeptides commonly
overexpressed on malignant cells surface. In this case,
it was possible to achieve a complete tumour ablation
in two xenograft models with no detectable toxicity in
comparison to controls [139].
Additional opportunities in this direction are
offered by introduction of specific targeting moieties,
which allow for the localised accumulation of the graphene-incorporating theranostic nanotools, thereby
dramatically reducing the side effects of the loaded
chemotherapeutic agents. Thus, the efficient use of graphene oxide which was conjugated to a targeting monoclonal antibody against follicle-stimulating hormone as
a highly selective tumour vasculature marker, has been
shown in a murine model of breast cancer metastasis
assisted by bioluminescence imaging. Histological analysis confirmed the active vascular accumulation of these
conjugates in lung metastatic nodules and tumours at
early time points. On top of this, such targeted graphene
oxide conjugates are promising for the use as theranostic tools due to a good anti-cancer drug loading capacity
[140]. Another group of authors has successfully utilised new somatostatin receptor-mediated tumour targeting nanotools based on octreotide-PEG conjugated
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Figure 4. The key factors affecting the toxicity of graphene, graphene-enabled products and opportunities for their targeted
functionalisation towards biomedical applications. PG—pristine graphene with varying number of layers (thickness), lateral
dimensions and sharpness. GO/rGO—graphene oxide/reduced graphene oxide. CF—chemical functionalisation (e.g. amine and
carboxyl groups). AL—accessory loading with magnetic nanomaterials (black spheres), photosensitizers (red spheres), lightemitting probes (yellow spheres) or biologically active compounds, e.g. anti-cancer drugs (green spheres). BC/ME—biocompatible
coating and/or matrix embedding (e.g. polymers). TLA—targeting ligands addition (proteins, antibodies, peptides etc).
FG—facilitated degradation (artificially induced and/or bio-degradation). The area marked by red dotted line denotes the structure
with several functionalities present at a time, which could be exploited in theranostic multimodal applications. Source: an original
illustration by the authors.

graphene oxide for combined chemo- and photothermal
therapy. These nanotools showed low systemic toxicity,
high efficiency of photothermal tumour ablation and
improved localised precision delivery of anti-cancer drug
doxorubicine [141].
The work of Zhou et al demonstrated that through
the implementation of bio-responsive nanosystems it is
possible not only to increase the efficacy of anti-cancer
nanodrugs, but also to significantly suppress the undesirable toxic side effects. They have constructed a multifunctional construct incorporating graphene oxide
with transferrin enabling receptor-mediated endocytosis and chemotherapeutic drugs load as therapeutic
modalities. This approach enabled to facilitate the cell
internalisation, accumulation and cytotoxic activity
of the construct against cancer cells, at the same time
showing less damaging impact on the normal cells.
This multifunctional nanodrug system triggered apoptosis in malignant cells through activation of p53 and
MAPK-dependent pathways and was simultaneously
leading to suppression of ERK and AKT-mediated signalling [142].
An example of a safe and efficient nanocomplex
for colon cancer drug delivery has been presented in
the form of a hydrogel designed using pH-sensitive
and biocompatible graphene oxide containing azoaromatic crosslinks, polyvinyl alcohol and an encapsulated
anti-cancer drug curcumin. The results of the studies in
colon-specific drug delivery systems demonstrated that
such composite hydrogels can protect the active drug
during passing through the aggressive environment of
the stomach and small intestine to the proximal colon
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and to enhance the colon-targeting ability and residence time in the colon, thereby preserving high drug
efficiency and maintaining low toxicity [143].
A remarkable stimulating effect on the biocompatibility and metabolic activity has been lately shown in
osteoblastic cell line MC3T3 and human mesenchymal
stem cells using polyethylene-immobilized, graphene
oxide reinforced high-density polyethylene nanocomposites [144]. In concert with these results, it has been
shown that graphene oxide-coated substrates stimulated the differentiation of mouse embryonic stem
cells to both primitive and definitive haematopoietic
cells. Notably, graphene oxide also facilitated human
embryonic stem cells differentiation to blood cells
thereby offering an intriguing opportunity for developing new strategies towards the generation of large
numbers of functional blood cells potentially exploitable in patients with blood disorders or hematologic
malignancies [145].
From the critical perspective, however, most of the
studies on the advanced multifunctional graphenebased nanosystems suffer a serious drawback as they
do not provide an insight into the long-term consequences of these applications intended for systemic
administration either due to the discontinuation of
the experiments upon reaching the desired registerable effects (e.g. statistically significant tumour volume reduction) or are limited by a natural lifespan of
small laboratory animals. This pressing issue undoubtedly must be addressed by the researchers investing
their efforts into the development of new generation
nanomedicines.
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7.4. Implantable devices and regenerative medicine
This promising area of biomedical applications of
GEP has deservedly received a steadily rising attention
over the last few years and has been lately extensively
covered in specialised topical overviews elsewhere
[146, 147]. However, we can’t omit addressing here
some of the elegant reports on graphene-enabled
products intended to be used as implantable devices
and scaffolds in human tissues in vivo. The study which
deserves a special attention in this regard implemented
electrospun microfibre scaffolds coated with selfassembled colloidal graphene which were implanted
into the striatum or into the subventricular zone of rat’s
brain. Amazingly, graphene coating was associated with
anti-inflammatory effects which manifested in reduced
microglia and astrocyte activation levels and prevented
glial scarring after 7 weeks post implantation. Among
the other registered effects were astrocyte guidance
within the scaffold and redirection of neuroblasts from
the subventricular zone along the implants [148]. This
observation has potentially far reaching repercussions
in the area of biocompatible sensors development and
neural tissue remodelling and regeneration.
Graphene has been also reported to exert beneficial
effects in dental and orthopaedic surgery by protecting dental implant surfaces against cariogenic bacteria
[149] and stimulating the morphogenetic processes via
facilitated osteogenic differentiation of mesenchymal
stem cells and surface bioactivity [150, 151], whilst
polypropylene fumarate nanocomposites in complex
with PEG-functionalized graphene oxide display no
cytotoxic effects in human dermal fibroblasts, making
them also remarkable candidates for the intended use in
orthodontic and general bone tissue engineering [89].
Altogether, the key factors affecting the toxicity of
graphene and its derivatives along with the exploitable
opportunities arising from selective GEP functionalisation for biomedical uses are summarised and schematically illustrated in figure 4.

8. Conclusions and future perspectives
A detailed analysis of the most recent original research
reports along with the earlier review publications
unequivocally confirms that graphene in any of its
numerous forms and derivatives must be approached as
a potentially hazardous material. It exerts its effects on a
widest range of living organisms, including prokaryotic
bacteria and viruses, plants, micro- and macroinvertebrates, eukaryotic mammalian and human
cells and whole animals in vivo. However, a significant
discrepancy and frequently even controversy existing
between different experimental findings conducted
even in closely related models dictates the demand
for further more systematic and coordinated multicentre research investigations including a detailed
physicochemical characterisation of the specific
graphene materials utilised in each study.
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Irrespective of the particular type of graphene
used, it is largely accepted that the generation of reactive oxygen species lies at the basis of its toxicity, further
attenuated by structural and chemical properties of the
nanomaterial. On this note, there is a clear difference
between the oxidised graphene forms most frequently
referred to and the pristine graphene which deserved
a much more modest attention, though even from the
limited number of comparative observations, it appears
to possess far less toxic potential. More extensive studies
in this area are therefore necessitated.
Graphene toxicity has been investigated in a variety of systems providing, to a certain extent, the imitation of physiologically relevant exposure scenarios in
humans. However, some of the most likely exposure
routes remain underexplored, such as for example, the
transcutaneous pathway, despite the fact that it could be
involved both in everyday life originating from the graphene-containing consumer products and in the future
as smart diagnostic devices and sensors developed for
dermal application. Therefore, we expect to see further
in-depth efforts of scientists in this direction.
With the emergence of new synthetic methods and
scale-up manufacturing processes we will undoubtedly
witness a steady increase in global graphene production
volumes. It is predicted that the graphene market will
grow to a total volume sales of 200 million $ (nearly 3.8 k
tonnes per annum) by 2020, according to IDTechEx
latest report. On this front, the implementation of effective risk management strategies at the manufacturing,
laboratory and clinical settings can minimise the exposure to graphene and its environmental discharge.
The increasing presence of graphene-enabled products on the market also dictates a demand for nanospecific scientific knowledge which has to provide the
basis for benchmarking, validation and trusted data
for the regulatory acceptance of GEP. However, despite
frameworks for acceptance have been developed by
now, there is the need to provide further insight into
the specific properties that are critical in determining
the transformation and behaviour of GEP. These will
allow for more efficient risk assessment and management strategies. The introduction of safe-by-design and
high benefit-to-risk ratio practices will also accelerate
the market approval and applications development for
the ultimate benefit of the patients and society.
Furthermore, numerous promising post-synthesis
approaches have already been offered targeting the
opportunities of efficient reduction of graphene hazardous features. Surface passivation, charge manipulation,
and introduction of biocompatible coatings are just a few
to list. Exploiting artificially induced degradation and/
or naturally operating catabolic pathways of graphene
represents another promising and intriguing window of
opportunity and it is of a particular importance in relation to bio-persistence and long-term toxicity of this
nanomaterial, since the extended (over several months)
in vivo monitoring studies in the area are extremely scarce.
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On another positive note, the double-edged sword
of graphene toxicity could be efficiently used for
exploitable beneficial opportunities. The established
antimicrobial activity of graphene can be utilised for
generation of new nano-enabled graphene-based disinfectants and bactericidal coatings with maximal efficacy
to exposure ratio and it is likely to be offered not in a
very distant future. Anti-cancer properties of graphene
nanomaterials, including selective cancer stem cell
targeting and a stream of very exciting studies demonstrating the possibilities of generating polyfunctional
graphene-based complexes for multimodal theranostic
applications lets us have an optimistic outlook on the
development of highly innovative nanotools for cancer
diagnostics, treatment and disease progression monitoring in the future.
We strongly believe that further consolidation of the
results of the new imminent in-depth studies in the unified graphene materials toxicity database reinforced by
the implementation of responsible manufacturing and
laboratory practices can contribute to the significant
reduction of risks inflicted by the potential graphene
exposure and help in establishing an appropriate educated awareness level in this field for the overall benefit
to the society.
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